Organic Electroluminescent Materials and Devices

ABSTRACT

Phosphorescent complexes are designed with intramolecular H-bonding properties to prevent deprotonation of neighboring molecules.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional patent application Ser. Nos. 61/979,103, filed Apr. 14, 2014, and 61/991,720, filed May 12, 2014, the entire contents of each of which is incorporated herein by reference.

PARTIES TO A JOINT RESEARCH AGREEMENT

The claimed invention was made by, on behalf of, and/or in connection with one or more of the following parties to a joint university corporation research agreement: Regents of the University of Michigan, Princeton University, University of Southern California, and the Universal Display Corporation. The agreement was in effect on and before the date the claimed invention was made, and the claimed invention was made as a result of activities undertaken within the scope of the agreement.

FIELD OF THE INVENTION

The present invention relates to compounds for use as emitters and devices, such as organic light emitting diodes, including the same.

BACKGROUND

Opto-electronic devices that make use of organic materials are becoming increasingly desirable for a number of reasons. Many of the materials used to make such devices are relatively inexpensive, so organic opto-electronic devices have the potential for cost advantages over inorganic devices. In addition, the inherent properties of organic materials, such as their flexibility, may make them well suited for particular applications such as fabrication on a flexible substrate. Examples of organic opto-electronic devices include organic light emitting devices (OLEDs), organic phototransistors, organic photovoltaic cells, and organic photodetectors. For OLEDs, the organic materials may have performance advantages over conventional materials. For example, the wavelength at which an organic emissive layer emits light may generally be readily tuned with appropriate dopants.

OLEDs make use of thin organic films that emit light when voltage is applied across the device. OLEDs are becoming an increasingly interesting technology for use in applications such as flat panel displays, illumination, and backlighting. Several OLED materials and configurations are described in U.S. Pat. Nos. 5,844,363, 6,303,238, and 5,707,745, which are incorporated herein by reference in their entirety.

One application for phosphorescent emissive molecules is a full color display. Industry standards for such a display call for pixels adapted to emit particular colors, referred to as “saturated” colors. In particular, these standards call for saturated red, green, and blue pixels. Color may be measured using CIE coordinates, which are well known to the art.

One example of a green emissive molecule is tris(2-phenylpyridine) iridium, denoted Ir(ppy)₃, which has the following structure:

In this, and later figures herein, we depict the dative bond from nitrogen to metal (here, Ir) as a straight line.

As used herein, the term “organic” includes polymeric materials as well as small molecule organic materials that may be used to fabricate organic opto-electronic devices. “Small molecule” refers to any organic material that is not a polymer, and “small molecules” may actually be quite large. Small molecules may include repeat units in some circumstances. For example, using a long chain alkyl group as a substituent does not remove a molecule from the “small molecule” class. Small molecules may also be incorporated into polymers, for example as a pendent group on a polymer backbone or as a part of the backbone. Small molecules may also serve as the core moiety of a dendrimer, which consists of a series of chemical shells built on the core moiety. The core moiety of a dendrimer may be a fluorescent or phosphorescent small molecule emitter. A dendrimer may be a “small molecule,” and it is believed that all dendrimers currently used in the field of OLEDs are small molecules.

As used herein, “top” means furthest away from the substrate, while “bottom” means closest to the substrate. Where a first layer is described as “disposed over” a second layer, the first layer is disposed further away from substrate. There may be other layers between the first and second layer, unless it is specified that the first layer is “in contact with” the second layer. For example, a cathode may be described as “disposed over” an anode, even though there are various organic layers in between.

As used herein, “solution processible” means capable of being dissolved, dispersed, or transported in and/or deposited from a liquid medium, either in solution or suspension form.

A ligand may be referred to as “photoactive” when it is believed that the ligand directly contributes to the photoactive properties of an emissive material. A ligand may be referred to as “ancillary” when it is believed that the ligand does not contribute to the photoactive properties of an emissive material, although an ancillary ligand may alter the properties of a photoactive ligand.

As used herein, and as would be generally understood by one skilled in the art, a first “Highest Occupied Molecular Orbital” (HOMO) or “Lowest Unoccupied Molecular Orbital” (LUMO) energy level is “greater than” or “higher than” a second HOMO or LUMO energy level if the first energy level is closer to the vacuum energy level. Since ionization potentials (IP) are measured as a negative energy relative to a vacuum level, a higher HOMO energy level corresponds to an IP having a smaller absolute value (an IP that is less negative). Similarly, a higher LUMO energy level corresponds to an electron affinity (EA) having a smaller absolute value (an EA that is less negative). On a conventional energy level diagram, with the vacuum level at the top, the LUMO energy level of a material is higher than the HOMO energy level of the same material. A “higher” HOMO or LUMO energy level appears closer to the top of such a diagram than a “lower” HOMO or LUMO energy level.

As used herein, and as would be generally understood by one skilled in the art, a first work function is “greater than” or “higher than” a second work function if the first work function has a higher absolute value. Because work functions are generally measured as negative numbers relative to vacuum level, this means that a “higher” work function is more negative. On a conventional energy level diagram, with the vacuum level at the top, a “higher” work function is illustrated as further away from the vacuum level in the downward direction. Thus, the definitions of HOMO and LUMO energy levels follow a different convention than work functions.

More details on OLEDs, and the definitions described above, can be found in U.S. Pat. No. 7,279,704, which is incorporated herein by reference in its entirety.

A proposed mechanism for the decomposition of complexes that contain an uncoordinated nitrogen is an event where the uncoordinated nitrogen acts as a base by deprotonating a neighboring molecule, leading to non-emissive and potentially ionic reaction products. This event may happen in the excited state or in the presence of charged states found in the device environment. However, some methods used to minimize protonation of the uncoordinated nitrogen may negatively affect other properties of the complex, such as by decreasing photoluminescent quantum yield (PLQY). There is a need in the art for novel compounds that are not susceptible to protonation of the uncoordinated nitrogen while maintaining desirable physical properties. The present invention addresses this unmet need.

SUMMARY OF THE INVENTION

According to an embodiment, a compound is provided comprising a ligand L selected from the group A consisting of:

wherein each X¹ to X¹³ are independently selected from the group consisting of carbon and nitrogen;

wherein X is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO₂, CRR′, SiRR′, and GeRR′;

wherein R and R′ are optionally fused or joined to form a ring;

wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution;

wherein each R, R′, R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein when R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) are optionally fused or joined to form a ring;

wherein the ligand L is coordinated to a metal M;

wherein the ligand L is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand;

wherein the compound comprises at least one intramolecular hydrogen bonding interaction as shown in the scheme:

Z¹—H—Z²,  scheme 1;

wherein Z¹ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen;

wherein Z² is selected from the group consisting of nitrogen, oxygen, and fluorine; and

wherein in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.3 ppm compared to the compound when Z² is carbon.

In one embodiment, in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.4 ppm compared to the compound when Z² is carbon. In another embodiment, the compound has an emission with the first peak wavelength at the high energy end smaller at room temperature than that at 77K. In another embodiment, Z¹ is carbon, and Z² is nitrogen. In another embodiment, Z¹ is carbon of alkyl, and Z² is nitrogen of pyridine. In another embodiment, M is selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Au, and Cu. In another embodiment, M is Ir or Pt. In another embodiment, the compound is homoleptic. In another embodiment, the compound is heteroleptic. In another embodiment, Z² is one of X¹ to X¹³, and is nitrogen. In another embodiment, Z¹ is at least 4 covalent bonds away from Z². In another embodiment, Z¹ is at least 5 covalent bonds away from Z². In another embodiment, X is O.

In one embodiment, the compound has a formula of Ir(L)_(n)(L′)_(3-n);

wherein L′ is selected from group A; and wherein n is 1, 2, or 3.

In one embodiment, n is 3. In another embodiment, L′ is different from L.

In one embodiment, the compound has a formula of Pt(L)_(m)(L′)_(2-m);

wherein L′ is selected from group A; and wherein m is 1, or 2.

In one embodiment, m is 1, and L and L′ are connected to form a tetradentate ligand. In another embodiment, m is 1; and L and L′ are connected at two places to form a macrocyclic tetradentate ligand.

In one embodiment, the ligand L is selected from the group consisting of:

In one embodiment, the compound is selected from the group consisting of:

According to another embodiment, a compound is provided that comprises a ligand L selected from the group A consisting of:

wherein each X¹ to X¹³ are independently selected from the group consisting of carbon and nitrogen;

wherein X is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO₂, CRR′, SiRR′, and GeRR′;

wherein R and R′ are optionally fused or joined to form a ring;

wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution;

wherein each R, R′, R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein when R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) are optionally fused or joined to form a ring;

wherein the ligand L is coordinated to a metal M;

wherein the ligand L is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand;

wherein the compound comprises at least one intramolecular hydrogen bonding interaction as shown in the scheme:

Z′—H—Z²,  scheme 1;

wherein Z′ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen;

wherein Z² is selected from the group consisting of nitrogen, oxygen, and fluorine; and

wherein in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 35% compared to the compound when Z² is carbon.

In one embodiment, the proton NMR chemical shift of H is shifted downfield by at least 37% compared to the compound when Z² is carbon.

According to another embodiment, a first device comprising a first organic light emitting device is also provided. The first organic light emitting device can include an anode, a cathode, and an organic layer, disposed between the anode and the cathode. The organic layer can include a compound comprising a ligand L. The first device can be a consumer product, an organic light-emitting device, an electronic component module, and/or a lighting panel.

In one embodiment, the first device comprises a first organic light emitting device, the first organic light emitting device comprising:

an anode;

a cathode; and

an organic layer, disposed between the anode and the cathode, comprising a compound comprising a ligand L selected from the group A consisting of

wherein each X¹ to X¹³ are independently selected from the group consisting of carbon and nitrogen;

wherein X is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO₂, CRR′, SiRR′, and GeRR′;

wherein R and R′ are optionally fused or joined to form a ring;

wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution;

wherein each R, R′, R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein when R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) are optionally fused or joined to form a ring;

wherein the ligand L is coordinated to a metal M;

wherein the ligand L is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand;

wherein the compound has at least one intramolecular hydrogen bonding interaction as shown in the scheme:

Z′—H—Z²,  scheme 1;

wherein Z¹ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen;

wherein Z² is selected from the group consisting of nitrogen, oxygen, and fluorine; and wherein;

(a) in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.3 ppm compared to the compound when Z² is carbon; or

(b) in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 35% compared to the compound when Z² is carbon.

In one embodiment, the first device is selected from the group consisting of a consumer product, an electronic component module, an organic light-emitting device, and a lighting panel. In another embodiment, the organic layer is an emissive layer and the compound is an emissive dopant or a non-emissive dopant. In another embodiment, the organic layer is a charge transporting layer and the compound is a charge transporting material in the organic layer. In another embodiment, the organic layer is a blocking layer and the compound is a blocking material in the organic layer.

In one embodiment, the organic layer further comprises a host; wherein the host comprises a triphenylene containing benzo-fused thiophene or benzo-fused furan; wherein any substituent in the host is an unfused substituent independently selected from the group consisting of C_(n)H_(2n+1), OC_(n)H_(2n+1), OAr₁, N(C_(n)H_(2n+1))₂, N(Ar₁)(Ar₂), CH═CH—C_(n)H_(2n+1), C≡CC_(n)H_(2n+1), Ar₁, Ar₁-Ar₂, C_(n)H_(2n)—Ar₁, or no substitution;

wherein n is from 1 to 10; and

wherein Ar₁ and Ar₂ are independently selected from the group consisting of benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.

In one embodiment, the organic layer further comprises a host, wherein the host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.

In one embodiment, the organic layer further comprises a host and the host is selected from the group consisting of:

and combinations thereof.

In one embodiment, the organic layer further comprises a host and the host comprises a metal complex.

According to another embodiment, a formulation comprising a compound of the invention is also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows an organic light emitting device.

FIG. 2 shows an inverted organic light emitting device that does not have a separate electron transport layer.

FIG. 3 shows the X-Ray crystal structure of Compound 1. The aryl substitution is twisted out of plane, shielding the lone pair of the uncoordinated nitrogen.

FIG. 4 shows an image of the minimized geometry for Compound 3. The methyl groups are configured to minimize steric interaction, forming a pocket around the nitrogen lone pair.

FIG. 5 shows an image of the minimized geometry of Compound 7. Two ligands have been removed for clarity.

FIG. 6 shows an image of the minimized geometry of Compound 13. Two ligands have been removed for clarity.

FIG. 7 shows an ¹H NMR spectrum of the ligand of Compound 7 in CD₂Cl₂ solvent.

FIG. 8 shows an ¹H NMR spectrum of the ligand of Compound 8 in CD₂Cl₂ solvent.

FIG. 9 shows an ¹H NMR spectrum of Compound 7 in CD₂Cl₂ solvent.

FIG. 10 shows an ¹H NMR spectrum of Compound 7 in DMSO-d₆ solvent.

FIG. 11 shows a room temperature and 77 K emission spectrum of Compound 7 in 2-MeTHF.

FIG. 12 shows a room temperature and 77 K emission spectrum of Compound 13 in 2-MeTHF.

DETAILED DESCRIPTION

Generally, an OLED comprises at least one organic layer disposed between and electrically connected to an anode and a cathode. When a current is applied, the anode injects holes and the cathode injects electrons into the organic layer(s). The injected holes and electrons each migrate toward the oppositely charged electrode. When an electron and hole localize on the same molecule, an “exciton,” which is a localized electron-hole pair having an excited energy state, is formed. Light is emitted when the exciton relaxes via a photoemissive mechanism. In some cases, the exciton may be localized on an excimer or an exciplex. Non-radiative mechanisms, such as thermal relaxation, may also occur, but are generally considered undesirable.

The initial OLEDs used emissive molecules that emitted light from their singlet states (“fluorescence”) as disclosed, for example, in U.S. Pat. No. 4,769,292, which is incorporated by reference in its entirety. Fluorescent emission generally occurs in a time frame of less than 10 nanoseconds.

More recently, OLEDs having emissive materials that emit light from triplet states (“phosphorescence”) have been demonstrated. Baldo et al., “Highly Efficient Phosphorescent Emission from Organic Electroluminescent Devices,” Nature, vol. 395, 151-154, 1998; (“Baldo-I”) and Baldo et al., “Very high-efficiency green organic light-emitting devices based on electrophosphorescence,” Appl. Phys. Lett., vol. 75, No. 3, 4-6 (1999) (“Baldo-II”), which are incorporated by reference in their entireties. Phosphorescence is described in more detail in U.S. Pat. No. 7,279,704 which is incorporated by reference in its entirety.

FIG. 1 shows an organic light emitting device 100. The figures are not necessarily drawn to scale. Device 100 may include a substrate 110, an anode 115, a hole injection layer 120, a hole transport layer 125, an electron blocking layer 130, an emissive layer 135, a hole blocking layer 140, an electron transport layer 145, an electron injection layer 150, a protective layer 155, a cathode 160, and a barrier layer 170. Cathode 160 is a compound cathode having a first conductive layer 162 and a second conductive layer 164. Device 100 may be fabricated by depositing the layers described, in order. The properties and functions of these various layers, as well as example materials, are described in more detail in U.S. Pat. No. 7,279,704 which is incorporated by reference in its entirety.

More examples for each of these layers are available. For example, a flexible and transparent substrate-anode combination is disclosed in U.S. Pat. No. 5,844,363, which is incorporated by reference in its entirety. An example of a p-doped hole transport layer is m-MTDATA doped with F4-TCNQ at a molar ratio of 50:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. Examples of emissive and host materials are disclosed in U.S. Pat. No. 6,303,238 to Thompson et al., which is incorporated by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li at a molar ratio of 1:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. U.S. Pat. Nos. 5,703,436 and 5,707,745, which are incorporated by reference in their entireties, disclose examples of cathodes including compound cathodes having a thin layer of metal such as Mg:Ag with an overlying transparent, electrically-conductive, sputter-deposited ITO layer. The theory and use of blocking layers is described in more detail in U.S. Pat. No. 6,097,147 and U.S. Patent Application Publication No. 2003/0230980, which are incorporated by reference in their entireties. Examples of injection layers are provided in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety. A description of protective layers may be found in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety.

FIG. 2 shows an inverted OLED 200. The device includes a substrate 210, a cathode 215, an emissive layer 220, a hole transport layer 225, and an anode 230. Device 200 may be fabricated by depositing the layers described, in order. Because the most common OLED configuration has a cathode disposed over the anode, and device 200 has cathode 215 disposed under anode 230, device 200 may be referred to as an “inverted” OLED. Materials similar to those described with respect to device 100 may be used in the corresponding layers of device 200. FIG. 2 provides one example of how some layers may be omitted from the structure of device 100.

The simple layered structure illustrated in FIGS. 1 and 2 is provided by way of non-limiting example, and it is understood that embodiments of the invention may be used in connection with a wide variety of other structures. The specific materials and structures described are exemplary in nature, and other materials and structures may be used. Functional OLEDs may be achieved by combining the various layers described in different ways, or layers may be omitted entirely, based on design, performance, and cost factors. Other layers not specifically described may also be included. Materials other than those specifically described may be used. Although many of the examples provided herein describe various layers as comprising a single material, it is understood that combinations of materials, such as a mixture of host and dopant, or more generally a mixture, may be used. Also, the layers may have various sublayers. The names given to the various layers herein are not intended to be strictly limiting. For example, in device 200, hole transport layer 225 transports holes and injects holes into emissive layer 220, and may be described as a hole transport layer or a hole injection layer. In one embodiment, an OLED may be described as having an “organic layer” disposed between a cathode and an anode. This organic layer may comprise a single layer, or may further comprise multiple layers of different organic materials as described, for example, with respect to FIGS. 1 and 2.

Structures and materials not specifically described may also be used, such as OLEDs comprised of polymeric materials (PLEDs) such as disclosed in U.S. Pat. No. 5,247,190 to Friend et al., which is incorporated by reference in its entirety. By way of further example, OLEDs having a single organic layer may be used. OLEDs may be stacked, for example as described in U.S. Pat. No. 5,707,745 to Forrest et al, which is incorporated by reference in its entirety. The OLED structure may deviate from the simple layered structure illustrated in FIGS. 1 and 2. For example, the substrate may include an angled reflective surface to improve out-coupling, such as a mesa structure as described in U.S. Pat. No. 6,091,195 to Forrest et al., and/or a pit structure as described in U.S. Pat. No. 5,834,893 to Bulovic et al., which are incorporated by reference in their entireties.

Unless otherwise specified, any of the layers of the various embodiments may be deposited by any suitable method. For the organic layers, preferred methods include thermal evaporation, ink-jet, such as described in U.S. Pat. Nos. 6,013,982 and 6,087,196, which are incorporated by reference in their entireties, organic vapor phase deposition (OVPD), such as described in U.S. Pat. No. 6,337,102 to Forrest et al., which is incorporated by reference in its entirety, and deposition by organic vapor jet printing (OVJP), such as described in U.S. Pat. No. 7,431,968, which is incorporated by reference in its entirety. Other suitable deposition methods include spin coating and other solution based processes. Solution based processes are preferably carried out in nitrogen or an inert atmosphere. For the other layers, preferred methods include thermal evaporation. Preferred patterning methods include deposition through a mask, cold welding such as described in U.S. Pat. Nos. 6,294,398 and 6,468,819, which are incorporated by reference in their entireties, and patterning associated with some of the deposition methods such as ink-jet and OVJD. Other methods may also be used. The materials to be deposited may be modified to make them compatible with a particular deposition method. For example, substituents such as alkyl and aryl groups, branched or unbranched, and preferably containing at least 3 carbons, may be used in small molecules to enhance their ability to undergo solution processing. Substituents having 20 carbons or more may be used, and 3-20 carbons is a preferred range. Materials with asymmetric structures may have better solution processibility than those having symmetric structures, because asymmetric materials may have a lower tendency to recrystallize. Dendrimer substituents may be used to enhance the ability of small molecules to undergo solution processing.

Devices fabricated in accordance with embodiments of the present invention may further optionally comprise a barrier layer. One purpose of the barrier layer is to protect the electrodes and organic layers from damaging exposure to harmful species in the environment including moisture, vapor and/or gases, etc. The barrier layer may be deposited over, under or next to a substrate, an electrode, or over any other parts of a device including an edge. The barrier layer may comprise a single layer, or multiple layers. The barrier layer may be formed by various known chemical vapor deposition techniques and may include compositions having a single phase as well as compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. The barrier layer may incorporate an inorganic or an organic compound or both. The preferred barrier layer comprises a mixture of a polymeric material and a non-polymeric material as described in U.S. Pat. No. 7,968,146, PCT Pat. Application Nos. PCT/US2007/023098 and PCT/US2009/042829, which are herein incorporated by reference in their entireties. To be considered a “mixture”, the aforesaid polymeric and non-polymeric materials comprising the barrier layer should be deposited under the same reaction conditions and/or at the same time. The weight ratio of polymeric to non-polymeric material may be in the range of 95:5 to 5:95. The polymeric material and the non-polymeric material may be created from the same precursor material. In one example, the mixture of a polymeric material and a non-polymeric material consists essentially of polymeric silicon and inorganic silicon.

Devices fabricated in accordance with embodiments of the invention can be incorporated into a wide variety of electronic component modules (or units) that can be incorporated into a variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include display screens, lighting devices such as discrete light source devices or lighting panels, etc. that can be utilized by the end-user product manufacturers. Such electronic component modules can optionally include the driving electronics and/or power source(s). Devices fabricated in accordance with embodiments of the invention can be incorporated into a wide variety of consumer products that have one or more of the electronic component modules (or units) incorporated therein. Such consumer products would include any kind of products that include one or more light source(s) and/or one or more of some type of visual displays. Some examples of such consumer products include flat panel displays, computer monitors, medical monitors, televisions, billboards, lights for interior or exterior illumination and/or signaling, heads-up displays, fully or partially transparent displays, flexible displays, laser printers, telephones, cell phones, tablets, phablets, personal digital assistants (PDAs), laptop computers, digital cameras, camcorders, viewfinders, micro-displays, 3-D displays, vehicles, a large area wall, theater or stadium screen, or a sign. Various control mechanisms may be used to control devices fabricated in accordance with the present invention, including passive matrix and active matrix. Many of the devices are intended for use in a temperature range comfortable to humans, such as 18 degrees C. to 30 degrees C., and more preferably at room temperature (20-25 degrees C.), but could be used outside this temperature range, for example, from −40 degree C. to +80 degree C.

The materials and structures described herein may have applications in devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors may employ the materials and structures. More generally, organic devices, such as organic transistors, may employ the materials and structures.

The term “halo,” “halogen,” or “halide” as used herein includes fluorine, chlorine, bromine, and iodine.

The term “alkyl” as used herein contemplates both straight and branched chain alkyl radicals. Preferred alkyl groups are those containing from one to fifteen carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like. Additionally, the alkyl group may be optionally substituted.

The term “cycloalkyl” as used herein contemplates cyclic alkyl radicals. Preferred cycloalkyl groups are those containing 3 to 7 carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl, and the like. Additionally, the cycloalkyl group may be optionally substituted.

The term “alkenyl” as used herein contemplates both straight and branched chain alkene radicals. Preferred alkenyl groups are those containing two to fifteen carbon atoms. Additionally, the alkenyl group may be optionally substituted.

The term “alkynyl” as used herein contemplates both straight and branched chain alkyne radicals. Preferred alkynyl groups are those containing two to fifteen carbon atoms. Additionally, the alkynyl group may be optionally substituted.

The terms “aralkyl” or “arylalkyl” as used herein are used interchangeably and contemplate an alkyl group that has as a substituent an aromatic group. Additionally, the aralkyl group may be optionally substituted.

The term “heterocyclic group” as used herein contemplates aromatic and non-aromatic cyclic radicals. Hetero-aromatic cyclic radicals also means heteroaryl. Preferred hetero-non-aromatic cyclic groups are those containing 3 or 7 ring atoms which includes at least one hetero atom, and includes cyclic amines such as morpholino, piperdino, pyrrolidino, and the like, and cyclic ethers, such as tetrahydrofuran, tetrahydropyran, and the like. Additionally, the heterocyclic group may be optionally substituted.

The term “aryl” or “aromatic group” as used herein contemplates single-ring groups and polycyclic ring systems. The polycyclic rings may have two or more rings in which two carbons are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles, and/or heteroaryls. Additionally, the aryl group may be optionally substituted.

The term “heteroaryl” as used herein contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine and pyrimidine, and the like. The term heteroaryl also includes polycyclic hetero-aromatic systems having two or more rings in which two atoms are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles, and/or heteroaryls. Additionally, the heteroaryl group may be optionally substituted.

The alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heterocyclic group, aryl, and heteroaryl may be optionally substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, cyclic amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.

As used herein, “substituted” indicates that a substituent other than H is bonded to the relevant position, such as carbon. Thus, for example, where R¹ is mono-substituted, then one R¹ must be other than H. Similarly, where R¹ is di-substituted, then two of R¹ must be other than H. Similarly, where R¹ is unsubstituted, R¹ is hydrogen for all available positions.

The “aza” designation in the fragments described herein, i.e. aza-dibenzofuran, aza-dibenzothiophene, etc. means that one or more of the C—H groups in the respective fragment can be replaced by a nitrogen atom, for example, and without any limitation, azatriphenylene encompasses both dibenzo[f,h]quinoxaline and dibenzo[f,h]quinoline. One of ordinary skill in the art can readily envision other nitrogen analogs of the aza-derivatives described above, and all such analogs are intended to be encompassed by the terms as set forth herein.

It is to be understood that when a molecular fragment is described as being a substituent or otherwise attached to another moiety, its name may be written as if it were a fragment (e.g. phenyl, phenylene, naphthyl, dibenzofuryl) or as if it were the whole molecule (e.g. benzene, naphthalene, dibenzofuran). As used herein, these different ways of designating a substituent or attached fragment are considered to be equivalent.

A proposed mechanism for the decomposition of complexes that contain an uncoordinated nitrogen is an event where the uncoordinated nitrogen acts as a base by deprotonating a neighboring molecule, leading to non-emissive and potentially ionic reaction products. This event may happen in the excited state or in the presence of charged states found in the device environment. Multi-ring scaffolds, such as the azaphenanthridine benzimidazole (APBI) ligand, may be useful to provide a functional site that can be substituted in order to address this decomposition mechanism.

Two approaches have been pursued in order to improve stability. The first approach places a steric group at the site in order to shield the lone pair of the uncoordinated nitrogen from exposure to protons on a neighboring molecule. For example, Compounds 1-6 contain substitution designed to sterically shield the nitrogen from protonation:

In Compound 1 and Compound 2, an aryl group is substituted on the ring opposite the uncoordinated nitrogen. Due to steric interaction, the ring is largely twisted out of plane, leading to a minimal increase in triplet energy. In addition, the plane of the aryl ring sits over the lone pair of the uncoordinated nitrogen, which should inhibit its exposure to nearby protons of neighboring molecules. The configuration of the aryl ring can be seen in the X-Ray crystal structure of Compound 1 (FIG. 3). However, an unexpected negative consequence of an aromatic substitution at this site is a decrease in PLQY. This can be mitigated to some extent by making the ring system more rigid by introducing 2,6-alkyl substitutions on the twisted aryl ring, such as in Compound 2. Compound 1 is measured to have a PLQY of 13% in a polymethylmethcrylate (PMMA) matrix. This improves markedly to 28% for Compound 2 with a more rigid 2,6-dimethyl phenyl substitution. However APBI complexes without aryl substitutions at this position typically have PLQY of 70-90%. The use of a non-aromatic substituent at the site of the uncoordinated nitrogen may be preferable in order to avoid the decrease in PLQY observed when the substituent is aromatic. For example, in the energy-minimized calculated geometry of Compound 3, which has non-aromatic substitution with a trimethylsilyl (TMS) group, the methyl groups of the TMS group point out of plane from the aromatic ring system, creating a pocket around the potentially-reactive lone pair of the uncoordinated nitrogen (FIG. 4).

As demonstrated herein, a second approach to improve stability comprises providing a hydrogen atom such that a static hydrogen bonding interaction is established between it and the lone pair of electrons on the uncoordinated nitrogen.

This configuration serves to mitigate the reactivity of the lone pair, stabilizing the molecule from intermolecular degradation, and therefore improving the stability of the complex in a device. An exemplary azaphenanthridine benzimidazole (APBI) ligand is depicted below, wherein the hydrogen is defined as H*:

It can be seen that H* points towards the lone pair of the nitrogen. It is believed that the proximity of the proton to the uncoordinated nitrogen is caused by steric repulsion between the methyl substituents on the isopropyl group and the ring system on the APBI. Using this strategy, complexes can be designed to place a proton in close proximity to the lone pair of the nitrogen in order to form a static intramolecular hydrogen bond. Therefore if the lone pair of the nitrogen were to increase in basicity in the excited or charged state, then the lone pair and H* should be able to reversibly interact. On the other hand, a molecule without an intramolecular hydrogen bond could induce an irreversible degradation event by deprotonating a nearby molecule in the excited or charged state.

Compounds of the Invention:

The compounds of the present invention may be synthesized using techniques well-known in the art of organic synthesis. The starting materials and intermediates required for the synthesis may be obtained from commercial sources or synthesized according to methods known to those skilled in the art.

In one aspect, the compound of the invention is a compound comprising a ligand L selected from the group A consisting of:

wherein each X¹ to X¹³ are independently selected from the group consisting of carbon and nitrogen;

wherein X is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO₂, CRR′, SiRR′, and GeRR′;

wherein R and R′ are optionally fused or joined to form a ring;

wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution;

wherein each R, R′, R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein when R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) are optionally fused or joined to form a ring;

wherein the ligand L is coordinated to a metal M;

wherein the ligand L is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand;

wherein the compound has at least one intramolecular hydrogen bonding interaction as shown in the scheme:

Z¹—H—Z²,  scheme 1;

wherein Z¹ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen;

wherein Z² is selected from the group consisting of nitrogen, oxygen, and fluorine; and

wherein in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.3 ppm compared to the compound when Z² is carbon.

In another aspect, the compound of the invention is a compound comprising a ligand L selected from the group A consisting of

wherein each X¹ to X¹³ are independently selected from the group consisting of carbon and nitrogen;

wherein X is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO₂, CRR′, SiRR′, and GeRR′;

wherein R and R′ are optionally fused or joined to form a ring;

wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution;

wherein each R, R′, R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein when R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) are optionally fused or joined to form a ring;

wherein the ligand L is coordinated to a metal M;

wherein the ligand L is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand;

wherein the compound has at least one intramolecular hydrogen bonding interaction as shown in the scheme:

Z¹—H—Z²,  scheme 1;

wherein Z′ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen;

wherein Z² is selected from the group consisting of nitrogen, oxygen, and fluorine; and

wherein;

(a) in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.3 ppm compared to the compound when Z² is carbon; or

(b) in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 35% compared to the compound when Z² is carbon.

In another aspect, the compound of the invention is a compound comprising a ligand L selected from the group A consisting of:

wherein each X¹ to X¹³ are independently selected from the group consisting of carbon and nitrogen;

wherein X is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO₂, CRR′, SiRR′, and GeRR′;

wherein R and R′ are optionally fused or joined to form a ring;

wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution;

wherein each R, R′, R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein when R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) are optionally fused or joined to form a ring;

wherein the ligand L is coordinated to a metal M;

wherein the ligand L is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand;

wherein the compound comprises at least one intramolecular hydrogen bonding interaction as shown in the scheme:

Z¹—H—Z²,  scheme 1;

wherein Z¹ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen;

wherein Z² is selected from the group consisting of nitrogen, oxygen, and fluorine; and

wherein in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 35% compared to the compound when Z² is carbon.

The metal M is not particularly limited. Examples of metals useful in the compounds of the present invention include, but are not limited to, transition metals such as Ir, Pt, Au, Re, Ru, W, Rh, Ru, Os, Pd, Ag, Cu, Co, Zn, Ni, Pb, Al, and Ga. In one embodiment, M is selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Au, and Cu. In another embodiment, M is Ir or Pt. In one embodiment, M is Ir. In another embodiment, M is Pt.

In one embodiment, X is selected from the group consisting of BR, NR, PR, O, S, Se, C═O, S═O, SO₂, CRR′, SiRR′, and GeRR′. In one embodiment, X is O.

In one aspect, the compounds of the invention include at least one intramolecular hydrogen bonding interaction to prevent deprotonation of neighboring molecules and to prevent protonation of an uncoordinated nitrogen. An exemplary intramolecular hydrogen bonding interaction can be found in scheme 1:

Z¹—H—Z²,  scheme 1.

As would be understood by one of ordinary skill in the art, Z¹ can be any atom capable of forming a covalent bond with H, while Z² can be any atom capable of forming a hydrogen bonding interaction with H. In one embodiment, Z¹ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen. In one embodiment, Z² is selected from the group consisting of nitrogen, oxygen, and fluorine. In another embodiment, Z¹ is carbon, and Z² is nitrogen. In another embodiment, Z¹ is carbon of alkyl, and Z² is nitrogen of pyridine. In another embodiment, Z² is one of X¹ to X¹³, and is nitrogen. In some embodiments, the location within the compound of Z¹ relative to Z² may be determined by the number of covalent bonds between Z¹ and Z². In one embodiment, Z¹ is at least 3 covalent bonds away from Z². In one embodiment, Z¹ is at least 4 covalent bonds away from Z². In another embodiment, Z¹ is at least 5 covalent bonds away from Z². In one embodiment, Z¹ is at least 6 covalent bonds away from Z².

An interaction between the hydrogen and Z² can be determined using any method known in the art. In one embodiment, the interaction is determined using computational methods, such as by inspecting the Z²—H distance and spatial positioning in the minimized geometry. In one embodiment, the distance between H and Z² ranges from 1.5 Å to 2.4 Å. In one embodiment, the distance between H and Z² is equal to or less than 2.2 Å. In another embodiment, the distance between H and Z² is equal to or less than 2.16 Å. In another embodiment, the distance between H and Z² is equal to or less than 2.15 Å. In another embodiment, the interaction is determined using experimental methods, such as by measuring the ¹H (proton) NMR chemical shift of the hydrogen-bonding proton. In one embodiment, the proton NMR chemical shift of H is shifted downfield by between 4.5 ppm and 7.0 ppm compared to the compound when Z² is carbon. In some embodiments, the NMR chemical shift of H may be shifted downfield by at least 1.3 ppm, at least 1.4 ppm, at least 1.5 ppm, at least 1.6 ppm, at least 1.7 ppm, at least 1.8 ppm, at least 1.9 ppm, or at least 2.0 ppm compared to the compound when Z² is carbon. In one embodiment, the proton NMR chemical shift of H is shifted downfield by at least 1.3 ppm compared to the compound when Z² is carbon. In another embodiment, the proton NMR chemical shift of H is shifted downfield by at least 1.4 ppm compared to the compound when Z² is carbon. In one embodiment, the proton NMR chemical shift of H is shifted downfield by between 30% and 60% compared to the compound when Z² is carbon. In some embodiments, the proton NMR chemical shift of H may be shifted downfield by at least 35%, at least 37%, at least 39%, at least 40%, at least 45%, or at least 50% compared to the compound when Z² is carbon. In one embodiment, the proton NMR chemical shift of H is shifted downfield by at least 35% compared to the compound when Z² is carbon. In another embodiment, the proton NMR chemical shift of H is shifted downfield by at least 37% compared to the compound when Z² is carbon

In one embodiment, the interaction is determined by measuring the emission of the first peak wavelength at the high energy end at room temperature and comparing it to the emission at a different temperature. As used herein, the term “room temperature” refers to a temperature from about 20° C. to about 30° C. As demonstrated herein, it was observed that compounds exhibiting an intramolecular hydrogen bonding interaction may also have an unusual triplet emission blue-shift in room temperature solution compared to the emission at a lower temperature. In one embodiment, the compound has an emission with the first peak wavelength at the high energy end smaller at room temperature than that at 77K.

In one embodiment, the ligand L is selected from the group consisting of:

In some embodiments, the compound is homoleptic. A compound may be homoleptic when it comprises two or more ligands L, wherein the two or more ligands L are the same ligands. In other embodiments, the compound is heteroleptic. A compound may be heteroleptic when it comprises two or more ligands L, wherein at least one of the ligands L is a different ligand from the other ligands L. In some embodiments, the compound comprises at least one ligand L and at least one ligand L′. In one embodiment, L′ is a different ligand from L. In another embodiment, L′ is the same ligand as L. In another embodiment, L is selected from group A. L′ is not particularly limited. In one embodiment, L′ is a bidentate ligand. Additionally, ligands L′ may be optionally substituted, and any adjacent substituents may be optionally fused or joined to form a ring or form a multidentate ligand. In some embodiments, L and L′ are connected to form a multidentate ligand, such as a tridentate, tetradentate, pentadentate, or hexadentate ligand. In one embodiment, L and L′ are connected to form a tetradentate ligand. L and L′ may be connected at one location or place to form a multidentate ligand, or L and L′ may be connected at two or more locations or places to form a macrocyclic multidentate ligand. In one embodiment, L and L′ are connected at two places to form a macrocyclic tetradentate ligand.

In one embodiment, the compound has a formula of Ir(L)_(n)(L′)_(3-n);

wherein L′ is selected from group A; and

wherein n is 1, 2, or 3.

In one embodiment, n is 1. In another embodiment, n is 2. In another embodiment, n is 3.

In one embodiment, the compound has a formula of Pt(L)_(m)(L′)_(2-m);

wherein L′ is selected from group A; and

wherein m is 1, or 2.

In one embodiment, m is 1. In another embodiment, m is 2.

In one embodiment, the compound is selected from the group consisting of:

In some embodiments, the compound can be an emissive dopant. In some embodiments, the compound can produce emissions via phosphorescence, fluorescence, thermally activated delayed fluorescence, i.e., TADF (also referred to as E-type delayed fluorescence), triplet-triplet annihilation, or combinations of these processes.

Devices:

According to another aspect of the present disclosure, a first device is also provided. The first device includes a first organic light emitting device, that includes an anode, a cathode, and an organic layer disposed between the anode and the cathode. The organic layer may include a host and a phosphorescent dopant. The emissive layer can include a compound comprising a ligand L, and its variations as described herein.

The first device can be one or more of a consumer product, an electronic component module, an organic light-emitting device and a lighting panel. The organic layer can be an emissive layer and the compound can be an emissive dopant in some embodiments, while the compound can be a non-emissive dopant in other embodiments. The organic layer can be a charge transporting layer and the compound can be a charge transporting material in the organic layer in some embodiments. The organic layer can be a blocking layer and the compound can be a blocking material in the organic layer in some embodiments.

The organic layer can also include a host. In some embodiments, the host can include a metal complex. The host can be a triphenylene containing benzo-fused thiophene or benzo-fused furan. Any substituent in the host can be an unfused substituent independently selected from the group consisting of C_(n)H_(2n+1), OC_(n)H_(2n+1), OAr₁, N(C_(n)H_(2n+1))₂, N(Ar₁)(Ar₂), CH═CH—C_(n)H_(2n+1), C≡C—C_(n)H_(2n+1), Ar₁, Ar₁-Ar₂, and C_(n)H_(2n)—Ar₁, or no substitution. In the preceding substituents n can range from 1 to 10; and Ar₁ and Ar₂ can be independently selected from the group consisting of benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.

The host can be a compound comprising at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene. The host can include a metal complex. The host can be a specific compound selected from the group consisting of:

and combinations thereof.

Formulations:

In yet another aspect of the present disclosure, a formulation that comprises a compound comprising a ligand L is described. The formulation can include one or more components selected from the group consisting of a solvent, a host, a hole injection material, hole transport material, and an electron transport layer material, disclosed herein.

Combination with Other Materials

The materials described herein as useful for a particular layer in an organic light emitting device may be used in combination with a wide variety of other materials present in the device. For example, emissive dopants disclosed herein may be used in conjunction with a wide variety of hosts, transport layers, blocking layers, injection layers, electrodes and other layers that may be present. The materials described or referred to below are non-limiting examples of materials that may be useful in combination with the compounds disclosed herein, and one of skill in the art can readily consult the literature to identify other materials that may be useful in combination.

HIL/HTL:

A hole injecting/transporting material to be used in the present invention is not particularly limited, and any compound may be used as long as the compound is typically used as a hole injecting/transporting material. Examples of the material include, but are not limited to: a phthalocyanine or porphyrin derivative; an aromatic amine derivative; an indolocarbazole derivative; a polymer containing fluorohydrocarbon; a polymer with conductivity dopants; a conducting polymer, such as PEDOT/PSS; a self-assembly monomer derived from compounds such as phosphonic acid and silane derivatives; a metal oxide derivative, such as MoO_(x); a p-type semiconducting organic compound, such as 1,4,5,8,9,12-Hexaazatriphenylenehexacarbonitrile; a metal complex, and cross-linkable compounds.

Examples of aromatic amine derivatives used in HIL or HTL include, but are not limited to the following general structures:

Each of Ar¹ to Ar⁹ is selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Wherein each Ar is further substituted by a substituent selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.

In one aspect, Ar¹ to Ar⁹ is independently selected from the group consisting of:

wherein k is an integer from 1 to 20; X¹⁰¹ to X¹⁰⁸ is C (including CH) or N; Z¹⁰¹ is NAr¹, O, or S; Ar¹ has the same group defined above.

Examples of metal complexes used in HIL or HTL include, but are not limited to the following general formula:

wherein Met is a metal, which can have an atomic weight greater than 40; (Y¹⁰¹-Y¹⁰²) is a bidentate ligand, Y¹⁰¹ and Y¹⁰² are independently selected from C, N, O, P, and S; L¹⁰¹ is an ancillary ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k″ is the maximum number of ligands that may be attached to the metal.

In one aspect, (Y¹⁰¹-Y¹⁰²) is a 2-phenylpyridine derivative. In another aspect, (Y¹⁰¹-Y¹⁰²) is a carbene ligand. In another aspect, Met is selected from Ir, Pt, Os, and Zn. In a further aspect, the metal complex has a smallest oxidation potential in solution vs. Fc⁺/Fc couple less than about 0.6 V.

Host:

The light emitting layer of the organic EL device of the present invention preferably contains at least a metal complex as light emitting material, and may contain a host material using the metal complex as a dopant material. Examples of the host material are not particularly limited, and any metal complexes or organic compounds may be used as long as the triplet energy of the host is larger than that of the dopant. While the Table below categorizes host materials as preferred for devices that emit various colors, any host material may be used with any dopant so long as the triplet criteria is satisfied.

Examples of metal complexes used as host are preferred to have the following general formula:

wherein Met is a metal; (Y¹⁰³-Y¹⁰⁴) is a bidentate ligand, Y¹⁰³ and Y¹⁰⁴ are independently selected from C, N, O, P, and S; L¹⁰¹ is an another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k″ is the maximum number of ligands that may be attached to the metal.

In one aspect, the metal complexes are:

wherein (O—N) is a bidentate ligand, having metal coordinated to atoms O and N.

In another aspect, Met is selected from Ir and Pt. In a further aspect, (Y¹⁰³-Y¹⁰⁴) is a carbene ligand.

Examples of organic compounds used as host are selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Wherein each group is further substituted by a substituent selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.

In one aspect, the host compound contains at least one of the following groups in the molecule:

wherein R¹⁰¹ to R¹⁰⁷ is independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, when it is aryl or heteroaryl, it has the similar definition as Ar's mentioned above. k is an integer from 0 to 20 or 1 to 20; k′″ is an integer from 0 to 20. X¹⁰¹ to X¹⁰⁸ is selected from C (including CH) or N. Z¹⁰¹ and Z¹⁰² is selected from NR¹⁰¹, O, or S.

HBL:

A hole blocking layer (HBL) may be used to reduce the number of holes and/or excitons that leave the emissive layer. The presence of such a blocking layer in a device may result in substantially higher efficiencies as compared to a similar device lacking a blocking layer. Also, a blocking layer may be used to confine emission to a desired region of an OLED.

In one aspect, the compound used in the HBL contains the same molecule or the same functional groups used as the host described above.

In another aspect, the compound used in the HBL contains at least one of the following groups in the molecule:

wherein k is an integer from 1 to 20; L¹⁰¹ is an another ligand, k′ is an integer from 1 to 3.

ETL:

Electron transport layer (ETL) may include a material capable of transporting electrons. Electron transport layer may be intrinsic (undoped), or doped. Doping may be used to enhance conductivity. Examples of the ETL material are not particularly limited, and any metal complexes or organic compounds may be used as long as they are typically used to transport electrons.

In one aspect, the compound used in ETL contains at least one of the following groups in the molecule:

wherein R¹⁰¹ is selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, when it is aryl or heteroaryl, it has the similar definition as Ar's mentioned above. Ar¹ to Ar³ has the similar definition as Ar's mentioned above. k is an integer from 1 to 20. X¹⁰¹ to X¹⁰⁸ is selected from C (including CH) or N.

In another aspect, the metal complexes used in ETL contains, but is not limited to, the following general formula:

wherein (O—N) or (N—N) is a bidentate ligand, having metal coordinated to atoms O, N or N, N; L¹⁰¹ is another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal.

In any above-mentioned compounds used in each layer of the OLED device, the hydrogen atoms can be partially or fully deuterated. Thus, any specifically listed substituent, such as, without limitation, methyl, phenyl, pyridyl, etc. encompasses undeuterated, partially deuterated, and fully deuterated versions thereof. Similarly, classes of substituents such as, without limitation, alkyl, aryl, cycloalkyl, heteroaryl, etc. also encompass undeuterated, partially deuterated, and fully deuterated versions thereof.

In addition to and/or in combination with the materials disclosed herein, many hole injection materials, hole transporting materials, host materials, dopant materials, exiton/hole blocking layer materials, electron transporting and electron injecting materials may be used in an OLED. Non-limiting examples of the materials that may be used in an OLED in combination with materials disclosed herein are listed in Table A below. Table A lists non-limiting classes of materials, non-limiting examples of compounds for each class, and references that disclose the materials.

TABLE A MATERIAL EXAMPLES OF MATERIAL PUBLICATIONS Hole injection materials Phthalocyanine and porphyrin compounds

Appl. Phys. Lett. 69, 2160 (1996) Starburst triarylamines

J. Lumin. 72-74, 985 (1997) CF_(x) Fluorohydrocarbon

Appl. Phys. Lett. 78, 673 (2001) polymer Conducting polymers (e.g., PEDOT:PSS, polyaniline, polythiophene)

Synth. Met. 87, 171 (1997) WO2007002683 Phosphonic acid and silane SAMs

US20030162053 Triarylamine or polythiophene polymers with conductivity dopants

EP1725079A1

Organic compounds with conductive inorganic compounds, such as molybdenum and tungsten oxides

US20050123751 SID Symposium Digest, 37, 923 (2006) WO2009018009 n-type semiconducting organic complexes

US20020158242 Metal organometallic complexes

US20060240279 Cross-linkable compounds

US20080220265 Polythiophene based polymers and copolymers

WO 2011075644 EP2350216 Hole transporting materials Triarylamines (e.g., TPD, α-NPD

Appl. Phys. Lett. 51, 913 (1987)

U.S. Pat. No. 5,061,569

EP650955

J. Mater. Chem. 3, 319 (1993)

Appl. Phys. Lett. 90, 183503 (2007)

Appl. Phys. Lett. 90, 183503 (2007) Triarylamine on spirofluorene core

Synth. Met. 91, 209 (1997) Arylamine carbazole compounds

Adv. Mater. 6, 677 (1994), US20080124572 Triarylamine with (di)benzothiophene/ (di)benzofuran

US20070278938, US20080106190 US20110163302 Indolocarbazoles

Synth. Met. 111, 421 (2000) Isoindole compounds

Chem. Mater. 15, 3148 (2003) Metal carbene complexes

US20080018221 Phosphorescent OLED host materials Red hosts Arylcarbazoles

Appl. Phys. Lett. 78, 1622 (2001) Metal 8- hydroxyquinolates (e.g., Alq₃, Balq)

Nature 395, 151 (1998)

US20060202194

WO2005014551

WO2006072002 Metal phenoxybenzothiazole compounds

Appl. Phys. Lett. 90, 123509 (2007) Conjugated oligomers and polymers (e.g., polyfluorene)

Org. Electron. 1, 15 (2000) Aromatic fused rings

WO2009066779, WO2009066778, WO2009063833, US20090045731, US20090045730, WO2009008311, US20090008605, US20090009065 Zinc complexes

WO2010056066 Chrysene based compounds

WO2011086863 Green hosts Arylcarbazoles

Appl. Phys. Lett. 78, 1622 (2001)

US20030175553

WO2001039234 Aryltriphenylene compounds

US20060280965

US20060280965

WO2009021126 Poly-fused heteroaryl compounds

US20090309488 US20090302743 US20100012931 Donor acceptor type molecules

WO2008056746

WO2010107244 Aza-carbazole/DBT/ DBF

JP2008074939

US20100187984 Polymers (e.g., PVK)

Appl. Phys. Lett. 77, 2280 (2000) Spirofluorene compounds

WO2004093207 Metal phenoxybenzooxazole compounds

WO2005089025

WO2006132173

JP200511610 Spirofluorene- carbazole compounds

JP2007254297

JP2007254297 Indolocarbazoles

WO2007063796

WO2007063754 5-member ring electron deficient heterocycles (e.g., triazole, oxadiazole)

J. Appl. Phys. 90, 5048 (2001)

WO2004107822 Tetraphenylene complexes

US20050112407 Metal phenoxypyridine compounds

WO2005030900 Metal coordination complexes (e.g., Zn, Al with N{circumflex over ( )}N ligands

US20040137268, US20040137267 Blue hosts Arylcarbazoles

Appl. Phys. Lett, 82, 2422 (2003)

US20070190359 Dibenzothiophene/ Dibenzofuran- carbazole compounds

WO2006114966, US20090167162

US20090167162

WO2009086028

US20090030202, US20090017330

US20100084966 Silicon aryl compounds

US20050238919

WO2009003898 Silicon/Germanium aryl compounds

EP2034538A Aryl benzoyl ester

WO2006100298 Carbazole linked by non-conjugated groups

US20040115476 Aza-carbazoles

US20060121308 High triplet metal organometallic complex

U.S. Pat. No. 7,154,114 Phosphorescent dopants Red dopants Heavy metal porphyrins (e.g., PtOEP)

Nature 395, 151 (1998) Iridium(III) organometallic complexes

Appl. Phys. Lett. 78, 1622 (2001)

US20030072964

US20030072964

US20060202194

US20060202194

US20070087321

US20080261076 US20100090591

US20070087321

Adv. Mater. 19, 739 (2007)

WO2009100991

WO2008101842

U.S. Pat. No. 7,232,618 Platinum(II) organometallic complexes

WO2003040257

US20070103060 Osmium(III) complexes

Chem. Mater. 17, 3532 (2005) Ruthenium(II) complexes

Adv. Mater. 17, 1059 (2005) Rhenium (I), (II), and (III) complexes

US20050244673 Green dopants Iridium(III) organometallic complexes

Inorg. Chem. 40, 1704 (2001)

US20020034656

U.S. Pat. No. 7,332,232

US20090108737

WO2010028151

EP1841834B

US20060127696

US20090039776

U.S. Pat. No. 6,921,915

US20100244004

U.S. Pat. No. 6,687,266

Chem. Mater. 16, 2480 (2004)

US20070190359

US 20060008670 JP2007123392

WO2010086089, WO2011044988

Adv. Mater. 16, 2003 (2004)

Angew. Chem. Int. Ed. 2006, 45, 7800

WO2009050290

US20090165846

US20080015355

US20010015432

US20100295032 Monomer for polymeric metal organometallic compounds

U.S. Pat. No. 7,250,226 U.S. Pat. No. 7,396,598 Pt(II) organometallic complexes, including polydentated ligands

Appl. Phys. Lett. 86, 153505 (2005)

Appl. Phys. Lett. 86, 153505 (2005)

Chem. Lett. 34, 592 (2005)

WO2002015645

US20060263635

US20060182992 US20070103060 Cu complexes

WO2009000673

US20070111026 Gold complexes

Chem. Commun. 2906 (2005) Rhenium(III) complexes

Inorg. Chem. 42, 1248 (2003) Osmium(II) complexes

U.S. Pat. No. 7,279,704 Deuterated organometallic complexes

US20030138657 Organometallic complexes with two or more metal centers

US20030152802

U.S. Pat. No. 7,090,928 Blue dopants Iridium(III) organometallic complexes

WO2002002714

WO2006009024

US20060251923 US20110057559 US20110204333

U.S. Pat. No. 7,393,599, WO2006056418, US20050260441, WO2005019373

U.S. Pat. No. 7,534,505

WO2011051404

U.S. Pat. No. 7,445,855

US20070190359, US20080297033 US20100148663

U.S. Pat. No. 7,338,722

US20020134984

Angew. Chem. Int. Ed. 47, 4542 (2008)

Chem. Mater. 18, 5119 (2006)

Inorg. Chem. 46, 4308 (2007)

WO2005123873

WO2005123873

WO2007004380

WO2006082742 Osmium(II) complexes

U.S. Pat. No. 7,279,704

Organometallics 23, 3745 (2004) Gold complexes

Appl. Phys. Lett. 74, 1361 (1999) Platinum(II) complexes

WO2006098120, WO2006103874 Pt tetradentate complexes with at least one metal- carbene bond

U.S. Pat. No. 7,655,323 Exciton/hole blocking layer materials Bathocuprine compounds (e.g., BCP, BPhen)

Appl. Phys. Lett. 75, 4 (1999)

Appl. Phys. Lett. 79, 449 (2001) Metal 8- hydroxyquinolates (e.g., Balq)

Appl. Phys. Lett. 81, 162 (2002) 5-member ring electron deficient heterocycles such as triazole, oxadiazole, imidazole, benzoimidazole

Appl. Phys. Lett. 81, 162 (2002) Triphenylene compounds

US20050025993 Fluorinated aromatic compounds

Appl. Phys. Lett. 79, 156 (2001) Phenothiazine-S-oxide

WO2008132085 Silylated five- membered nitrogen, oxygen, sulfur or phosphorus dibenzoheterocycles

WO2010079051 Aza-carbazoles

US20060121308 Electron transporting materials Anthracene- benzoimidazole compounds

WO2003060956

US20090179554 Aza triphenylene derivatives

US20090115316 Anthracene- benzothiazole compounds

Appl. Phys. Lett. 89, 063504 (2006) Metal 8- hydroxyquinolates (e.g., Alq₃, Zrq₄)

Appl. Phys. Lett. 51, 913 (1987) U.S. Pat. No. 7,230,107 Metal hydroxybenzoquinolates

Chem. Lett. 5, 905 (1993) Bathocuprine compounds such as BCP, BPhen, etc

Appl. Phys. Lett. 91, 263503 (2007)

Appl. Phys. Lett. 79, 449 (2001) 5-member ring electron deficient heterocycles (e.g., triazole, oxadiazole, imidazole, benzoimidazole)

Appl. Phys. Lett. 74, 865 (1999)

Appl. Phys. Lett. 55, 1489 (1989)

Jpn. J. Apply. Phys. 32, L917 (1993) Silole compounds

Org. Electron. 4, 113 (2003) Arylborane compounds

J. Am. Chem. Soc. 120, 9714 (1998) Fluorinated aromatic compounds

J. Am. Chem. Soc. 122, 1832 (2000) Fullerene (e.g., C60)

US20090101870 Triazine complexes

US20040036077 Zn (N{circumflex over ( )}N) complexes

U.S. Pat. No. 6,528,187

EXPERIMENTAL

Non-limiting examples of compounds of the invention that contain intramolecular hydrogen bonding include:

These complexes have been designed to place a proton in close proximity to the lone pair of the nitrogen in order to form a static intramolecular hydrogen bond. A spectrophotometric signature of this interaction may also be observed in the unusual triplet emission blue-shift in room temperature solution compared to 77K.

Addressing the computational evidence for an intramolecular hydrogen bonding event, the minimized geometry for Compound 7 is shown in FIG. 5. Two ligands have been removed for clarity. It can be seen that H* is slightly above the plane of the lone pair of the nitrogen with a C—C—C—H dihedral angle of 31.6° and a H*—N distance of 2.15 Å. Although not wishing to be bound by any particular theory, it is hypothesized that the proximity of the proton to the uncoordinated nitrogen is caused by steric repulsion between the methyl substituents on the isopropyl group and the ring system on the APBI. This hypothesis is supported by comparison against the methyl-substituted Compound 13 (FIG. 6), in which no direct N—H* interaction is observed and the protons on the methyl group point as far from the nitrogen lone pair as physically possible.

In this case the C—C—C—H dihedral is 61.8°, and the N—H* bond distance is 2.52 Å. Minimized geometries for Compound 8 and Compound 9 show a similar N—H* interaction to Compound 7. The C—C—C—H dihedral angle and N—H* bond distance for Compound 8 are 34.7° and 2.16 Å, respectively. The C—C—C—H dihedral angle of interest is highlighted below:

The experimental evidence for a static intramolecular hydrogen bond to the lone pair of the uncoordinated nitrogen is observable in the ¹H NMR for both the free ligand and iridium complex. For reference, the methyl protons for the ligand of Compound 13 are measured at 3.26 ppm in CD₂Cl₂. In comparison, the H* protons in the ligands of Compounds 7 and 8 are shifted significantly downfield to 5.6 ppm and 5.2 ppm, respectively, as shown in FIG. 7 and FIG. 8. A similar downfield shift is observed after cyclometalation to iridium(III), as demonstrated in the ¹H NMR spectra for Complex 7 in CD₂Cl₂ and DMSO-d₆ (FIGS. 9 and 10, respectively), with chemical shifts of 5.9 ppm irrespective of solvent polarity. This downfield shift is a result of the well-understood phenomenon of hydrogen-bonding-induced proton de-shielding, indicative of an intramolecular hydrogen-bonding interaction.

The ¹H NMR chemical shifts of H* were also calculated for the ligands and their corresponding compounds of Compound 7, Compound 8 and Compound 13, together with Comparative Examples 1 to 8. Calculations were carried out using the B3LYP/6-31g* functional and basis set on the Gaussian software package. The calculated values match very closely to the experimental values. Further evidence of intramolecular H-bonding is found by comparing the calculated chemical shift of H* to Comparative Examples 1-8, where intramolecular H-bonding is not available. In all of these cases, NMR chemical shifts of H* in C—H*—N analogs are all significantly shifted downfield compared to their C—H*—C analogs, with differences ranging from 1.4 to 2.1 ppm, or from 37% to 50% based on C—H*—C analogs (Table 1).

TABLE 1 Experimental and calculated chemical shifts of H* Experimental chemical shift of H* (ppm) Calculated chemical shift of H* (ppm) Difference (ppm), and percentage Difference (ppm), and percentage Compound

Structures having similar structure having similar structure

5.59 5.5 1.5, 37.5% (vs Comparative Example 1) Ligand of Compound 7

4.0 Comparative Example 1

5.11 1.43, 38.9% (vs Comparative Example 4) 5.2 1.5, 40.5% (vs Comparative Example 2) 1.5, 40.5% (vs Comparative Example 4) Ligand of Compound 8

3.7 Comparative Example 2

3.68 3.7 Comparative Example 4

3.24 3.1 0.2, 6.9% (vs Comparative Example 3) Ligand of Compound 13

2.9 Comparative Example 3

5.96 (for mer^(a)) 6.3 2.1, 50% (vs Comparative Example 6) Compound 7

4.2 Comparative Example 6

5.45 1.56, 40.1% (vs Comparative Example 5) 6.0 2.0, 50% (vs Comparative Example 7) 2.0, 50% (vs Comparative Example 5) Compound 8

4.0 Comparative Example 7

3.89 4.0 Comparative Example 5

3.35 3.6 0.5, 16% (vs Comparative Example 8) Compound 13

3.1 Comparative Example 8 ^(a)all data shown in the table for Ir complexes are based on fac isomer, except for this one.

Additional evidence of an H bonding interaction can be found in a feature of the emission spectra of Compound 7. FIG. 11 shows the emission spectra of Compound 7 in 2-methyl tetrahydrofuran (2-MeTHF) solvent at room temperature and 77 K. The room temperature emission was found to be significantly blue-shifted relative to 77 K, unlike any other Ir(APBI)₃ complex yet measured. Although not wishing to be bound by any particular theory, it is hypothesized that this blue shift may be due to an inductive withdrawing effect, which reduces electron density on the covalently attached ring, thereby blue shifting the emission spectra. Although not wishing to be bound by any particular theory, the fact that this effect is more significant at room temperature is suggestive of a vibrational interaction between the H and N atoms which is frozen out at 77 K. For comparison purposes, the spectrum for Compound 13 is shown in FIG. 12. This compound shows a blue shift as the molecule is rigidified at 77K, typical of most phosphorescent complexes.

Synthesis of exemplary ligands and complexes:

Synthesis of Compound 7: Synthesis of 10-chlorobenzo[h][1,6]naphthyridin-5-amine

A mixture of 3-chloro-2-iodoaniline (9.60 g, 37.9 mmol), CyJohnPhos (0.506 g, 1.443 mmol), and Pd(CH₃CN)₂Cl₂ (0.187 g, 0.722 mmol) was dissolved in dioxane (80 ml). Triethylamine (15.09 ml, 108 mmol) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (11.00 ml, 76 mmol) were added to the solution in sequence via syringe. The reaction was refluxed for 4 h. The reaction was cooled to R.T. and a solid mixture of 2-chloronicotinonitrile (5 g, 36.1 mmol), S-Phos Pd G2 (0.520 g, 0.722 mmol), S-Phos (0.296 g, 0.722 mmol), and potassium carbonate (9.97 g, 72.2 mmol) was added to the reaction mixture directly followed by the addition of dioxane (20 ml) and water (20 ml) and the reaction was heated to 85° C. overnight. Dioxane was removed and the crude product was extracted with dichloromethane (DCM). The organic part was evaporated to provide an oily product. The product was dissolved in THF (80 mL), and sodium hydride (2.165 g, 54.1 mmol) was directly added at 0° C. and stirred for 25 min. The reaction was quenched with brine (˜150 mL). After THF was evaporated, hexanes and diethyl ether (˜1:2, roughly 30 mL in total) were added to the suspension, which was then stirred for about 3 min. The solids were collected by filtration and washed with diethyl ether to afford crude 10-chlorobenzo[h][1,6]naphthyridin-5-amine, which was directly used in the next step without further purification (60% yield).

Synthesis of 5-chlorobenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine

A mixture of 10-chlorobenzo[h][1,6]naphthyridin-5-amine (3.11 g, 13.54 mmol), diacetoxypalladium (0.152 g, 0.677 mmol), Xantphos (0.392 g, 0.677 mmol), and cesium carbonate (17.65 g, 54.2 mmol) was vacuumed and back-filled with nitrogen several times, and 1,2-diiodobenzene (1.947 ml, 14.90 mmol) and toluene (70 ml) were added to the solution. The reaction was refluxed for 3 h. The product was purified by column chromatography on silica (DCM/MeOH=20/1). The product was washed with diethyl ether (52% yield).

Synthesis of 5-(prop-1-en-2-yl)benzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine

A mixture of 5-chlorobenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (1 g, 3.29 mmol), SPhos Pd G2 (0.237 g, 0.329 mmol), SPhos (0.135 g, 0.329 mmol), and cesium carbonate (0.536 g, 1.646 mmol) was vacuumed and back-filled with nitrogen several times. Toluene (45 ml), Water (15 ml), and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (1.257 ml, 6.58 mmol) were added and heated at reflux overnight. The reaction mixture was coated on celite and chromatographed on silica (DCM/EtOAc/heptanes=6/1/2) (50% yield).

Synthesis of 5-isopropylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine

5-(prop-1-en-2-yl)benzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (1.05 g, 3.39 mmol) was dissolved in ethyl acetate (60 ml) and, and ethanol (50 ml) and palladium (0.361 g, 0.339 mmol) were added. The reaction mixture was vacuumed and back-filled with a hydrogen balloon three times and stirred at R.T. overnight. The reaction was filtered through Celite and the solvent was evaporated. The solid was washed with diethyl ether and hexane (˜1:2) to afford pure product (99% yield).

Synthesis of Compound 7:

5-isopropylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (900 mg, 2.89 mmol), Ir(acac)₃ (283 mg, 0.578 mmol), and pentadecane (2 mL) were combined in a Schlenk tube and the tube was vacuumed and back-filled with N₂ three times. The tube was heated to 290° C. for 2 days. The crude product was purified by column chromatography on alumina (100 g, deactivated with 10% H₂O, DCM/Hep=3/2). The product was further purified on silica gel column (DCM) to yield Compound 7 (15.4%).

Synthesis of Compound 8: Synthesis of 5-(cyclohex-1-en-1-yl)benzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine

A mixture of 5-chlorobenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (2.13 g, 7.01 mmol), SPhos Pd G2 (0.505 g, 0.701 mmol), SPhos (0.288 g, 0.701 mmol), and potassium phosphate monohydrate (4.84 g, 21.04 mmol) was vacuumed and back-filled with nitrogen several times. Toluene (75 ml), Water (25 ml), and 2-(cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.292 ml, 10.52 mmol) were added and heated at reflux overnight. The reaction was extracted with DCM and brine and purified by column chromatography on silica (EA/Hep=1/3) (75% yield).

Synthesis of Ligand of Compound 8:

Dissolved 5-(cyclohex-1-en-1-yl)benzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (1.59 g, 4.55 mmol) in Ethyl acetate (90 ml) and added Ethanol (70 ml) and palladium (0.484 g, 0.455 mmol). The reaction mixture was vacuumed and back-filled with a hydrogen balloon three times and stirred at R. T. for 3 days. The reaction was filtered through Celite and evaporated. The product was purified by column chromatography on silica with pure EA (54% yield).

Synthesis of Compound 8:

A mixture of 5-cyclohexylbenzo[h]benzo[4,5]imidazo[2,1-f][1,6]naphthyridine (1 g, 2.85 mmol), Ir(acac)₃ (279 mg, 0.569 mmol), and pentadecane (4 mL) were added to an acid digestion bomb in a glove box and heated at 285° C. in a sand bath overnight. The product was purified by column chromatography on silica column (DCM). The product was triturated in MeOH and diethyl ether and filtered (26% yield).

Synthesis of Comparative Example 5 Synthesis of 1-chlorophenanthridin-6-amine

A mixture of 3-chloro-2-iodoaniline (8.77 g, 34.6 mmol), CyJohnPhos (0.462 g, 1.319 mmol), and Pd(CH₃CN)₂Cl₂ (0.171 g, 0.659 mmol) was dissolved in dioxane (80 ml). Triethylamine (13.78 ml, 99 mmol) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (10.04 ml, 69.2 mmol) were added to the solution in sequence via syringe. The reaction was refluxed for 4 h. The reaction was cooled to R.T. and a solid mixture of 2-bromobenzonitrile (6 g, 33 mmol), S-Phos Pd G2 (0.475 g, 0.659 mmol), S-Phos (0.271 g, 0.659 mmol), and potassium carbonate (9.11 g, 65.9 mmol) was added to the reaction mixture directly followed by the addition of dioxane (20 ml) and water (20 ml) and the reaction was heated to 85° C. overnight. Dioxane was removed and the crude product was extracted with dichloromethane (DCM). The organic part was evaporated to provide an oily product. The product was dissolved in THF (80 mL), and sodium hydride (1.978 g, 49.4 mmol) was directly added at 0° C. and stirred for 20 min. The reaction was quenched with brine (˜150 mL). The THF was evaporated and the crude product was extracted with DCM and brine. Solid was collected by trituration in diethyl ether and hexane (52% yield).

1-chlorophenanthridin-6-amine (3.93 g, 17.19 mmol), 2-chloroacetaldehyde (4.68 mL, 34.4 mmol), and sodium bicarbonate (2.89 g, 34.4 mmol) were combined and refluxed for 2 h. The reaction mixture was extracted with 10% MeOH in DCM and brine. The crude product was purified by column chromatography on silica (DCM/MeOH=9/1). The product was washed with diethyl ether and hexane to afford 8-chloroimidazo[1,2-f]phenanthridine (78%).

Synthesis of Ligand of Comparative Example 5

A mixture of 8-chloroimidazo[1,2-f]phenanthridine (900 mg, 3.56 mmol) and SPhos Pd G2 (128 mg, 0.178 mmol) was vacuumed and back-filled with nitrogen several times. THF (40 ml) and cyclohexylzinc(II) bromide (14.25 ml, 7.12 mmol) were added via an addition funnel and stirred at R.T. overnight. The reaction was quenched with water and extracted with DCM. Crude product was chromatographed on silica (EA) to afford 8-cyclohexylimidazo[1,2-f]phenanthridine (80% yield).

Synthesis of Comparative Example 5

8-cyclohexylimidazo[1,2-f]phenanthridine (180 mg, 5.99 mmol), Ir(acac)₃ (58.7 mg, 120 mmol), and tridecane (0.8 mL) were combined in an acid digestion bomb in glove box and heated at 245° C. in a sand bath overnight. The product was purified by column chromatography on silica column (DCM) (60% yield).

It is understood that the various embodiments described herein are by way of example only, and are not intended to limit the scope of the invention. For example, many of the materials and structures described herein may be substituted with other materials and structures without deviating from the spirit of the invention. The present invention as claimed may therefore include variations from the particular examples and preferred embodiments described herein, as will be apparent to one of skill in the art. It is understood that various theories as to why the invention works are not intended to be limiting.

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations. 

1. A compound comprising a ligand L selected from the group A consisting of:

wherein each X¹ to X², and X⁷ to X¹³, are carbon, and X³ to X⁶ are independently selected from carbon or nitrogen; wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution; wherein each R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, phosphino, and combinations thereof; or if R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) can join to form a ring; wherein the ligand L is coordinated to a metal M selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Au, and Cu; and the ligand L is optionally linked with other ligands to form a tridentate, tetradentate, pentadentate or hexadentate ligand to the metal M; wherein the compound comprises at least one intramolecular hydrogen bonding interaction as shown in the scheme: Z¹—H—Z²,  scheme 1; wherein Z¹ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen; wherein Z² is nitrogen and is one of X³ to X⁶; and wherein in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.3 ppm compared to the compound when Z² is carbon.
 2. The compound of claim 1, wherein in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.4 ppm compared to the compound when Z² is carbon.
 3. The compound of claim 1, wherein the compound has an emission with the first peak wavelength at the high energy end smaller at room temperature than that at 77K.
 4. The compound of claim 1, wherein Z¹ is carbon, and Z² is nitrogen.
 5. The compound of claim 1, wherein Z¹ is carbon of alkyl, and Z² is nitrogen of pyridine.
 6. The compound of claim 1, wherein M is Pt and the ligand L is selected from


7. The compound of claim 1, wherein M is Ir or Pt. 8.-13. (canceled)
 14. The compound of claim 1, wherein the compound has a formula of Ir(L)_(n)(L′)_(3-n); wherein the ligand L is different from L′; and n is 1, 2, or
 3. 15. The compound of claim 14, wherein n is
 3. 16. (canceled)
 17. The compound of claim 1, wherein the compound has a formula of Pt(L)_(m)(L′)_(2-m); wherein the ligand L is different from L′, and L and L′ are connected to form a tetradentate ligand; and m is 1, or
 2. 18.-19. (canceled)
 20. The compound of claim 1, wherein the ligand L is selected from the group consisting of:


21. The compound of claim 1, wherein the compound is selected from the group consisting of:


22. A first device comprising a first organic light emitting device, the-first organic light emitting device comprising: an anode; a cathode; and an organic layer, disposed between the anode and the cathode, comprising a compound comprising a ligand L selected from the group A consisting of:

wherein each X¹ to X², and X⁷ to X¹³, are carbon, and X³ to X⁶ are independently selected from carbon or nitrogen; wherein each R_(a), R_(b), R_(c), and R_(d) may represent from mono substitution to the possible maximum number of substitution, or no substitution; wherein each R_(a), R_(b), R_(c), and R_(d) are independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, phosphino, and combinations thereof; or if R_(a), R_(b), R_(c), and R_(d) represent at least di substitution, each of the two adjacent R_(a), two adjacent R_(b), two adjacent R_(c), and two adjacent R_(d) can join to form a ring; wherein the ligand L is coordinated to a metal M selected from the group consisting of Ir, Rh, Re, Ru, Os, Pt, Au, and Cu; and the ligand L is optionally linked with other ligands to form a tridentate, tetradentate, pentadentate or hexadentate ligand to the metal M; wherein the compound comprises at least one intramolecular hydrogen bonding interaction as shown in the scheme: Z¹—H—Z²,  scheme 1; wherein Z¹ is selected from the group consisting of carbon, silicon, nitrogen, and oxygen; wherein Z² is nitrogen and is one of X³ to X⁶; and wherein in scheme 1, the proton NMR chemical shift of H is shifted downfield by at least 1.3 ppm compared to the compound when Z² is carbon.
 23. The first device of claim 22, wherein the first device is selected from the group consisting of a consumer product, an electronic component module, an organic light-emitting device, and a lighting panel.
 24. The first device of claim 22, wherein the organic layer is an emissive layer and the compound is an emissive dopant or a non-emissive dopant. 25.-26. (canceled)
 27. The first device of claim 22, wherein the organic layer further comprises a host; wherein the host comprises a triphenylene containing benzo-fused thiophene or benzo-fused furan; wherein any substituent in the host is an unfused substituent independently selected from the group consisting of C_(n)H_(2n+1), OC_(n)H_(2n+1), OAr₁, N(C_(n)H_(2n+1))₂, N(Ar₁)(Ar₂), CH═CH—C_(n)H_(2n+1), C≡CC_(n)H_(2n+1), Ar₁, Ar₁-Ar₂, C_(n)H_(2n)—Ar₁, or no substitution; wherein n is from 1 to 10; and wherein Ar₁ and Ar₂ are independently selected from the group consisting of benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.
 28. The first device of claim 22, wherein the organic layer further comprises a host, wherein the host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.
 29. The first device of claim 22, wherein the organic layer further comprises a host and the host is selected from the group consisting of:

and combinations thereof. 30.-33. (canceled)
 34. The first device of claim 22, wherein the ligand L is selected from the group consisting of:


35. The first device of claim 22, wherein the ligand L is selected from the group consisting of: 